We’re passionate about being well
Our Vision is to create, from the ground up, a Centre of excellence which nurtures early stage, often fragile, start-ups, so they become scalable World renowned Companies which deliver measurable improvements in human Wellness. Our work will have impact far beyond our geographical base in the Isle of Man, British Isles.
The Venerable Brian Partington, O.B.E, is a retired Anglican clergyman and former Archdeacon of the Isle of Man; he has worked in the Manx community for nearly fifty years. He has been actively involved with a number of charities including Hospice IOM, of which he is a former Chairman and is still President. From 1990 – 2002 he was Executive Chairman of the IOM Sports Council and led the development of many projects including the building and development of the National Sports Council and the hosting of the NatWest Island Games in 2001. He became Vice-Chairman and the Chairman of the International Island Games Association. He has worked closely with the IOM Government in the former Department of Tourism and Leisure and latterly as member of the Isle of Man Post Office Board.
Dr Brian Whittle
Dr Brian Whittle, MSc, PhD, FRPhS, B Pharm, MSc, PhD, serves as a Scientific Advisor of Phynova Group PLC. Dr Whittle co-founded GW Pharmaceuticals PLC and served as its Scientific Director until March 2008. Dr Whittle has 40 years experience in the pharmaceutical industry. He co-founded Phytopharm PLC and served as its Chief Executive from 1990 to 1994 and Chief Scientific Officer from 1994 and 1998. Dr Whittle also founded Brian Whittle Associates Ltd, and has held senior positions at Wyeth Europa Ltd, Reckitt and Colman plc, and ICI Pharmaceuticals Ltd.
Dom is a leading intellectual property (IP) attorney in the field of botanical medicines and external IP legal counsel for two of the world’s leading botanical medicine companies: GW Pharmaceuticals and Phynova. Dom has significant experience in protecting, licencing and exploitation of natural products IP (Intellectual Property). Additional experience includes algal bio-fermentation, stem cells, nutraceuticals, novel drug delivery methods, coated nano-particles, additive manufacturing, and augmented & virtual reality. He also runs his own business incubator 4748 Limited with bespoke accommodation in Liverpool.
Dr Kavita Bhagwat
Director-Pharma‐Synergies Limited, Isle of Man. Kavita has a PhD in Pharmacy with 20+ years experience both in academia and in the pharmaceutical industry including start-ups, global pharma and CRO’s (Contract Research Organisations). She has extensive experience in biotechnology products (advanced therapy medicinal products, somatic cell therapy products and tissue engineered products), speciality pharmaceuticals, medical devices, drug-device combinations, botanical therapeutics and OTC (Over The Counter) products. Kavita is a Regulatory Affairs and Clinical Research Consultant engaged in providing specialist Regulatory Affairs and Clinical Research Consultancy through her company ‘Pharma‐Synergies Limited.
Dr Tariq Ali
Dr Tariq Ali has over 20 years of academic and industrial experience in protein chemistry and molecular biology. He gained his PhD from The University of Cambridge and worked as a research associate at the University of Oxford. He has a specific interest and expertise in upstream and downstream protein production. He has been directly involved in the development of ADCs and orphan disease ‘biologics’ and imaging agents for cancer diagnosis and treatment. Dr Ali also has experience and expertise in biosensor development, anti- counterfeiting and discovery of new near infra-red fluorescent (NIRF) proteins.
Paul was a former tax partner at KPMG and has been involved in a wide variety of industries and companies. Paul operates from the Isle of Man and is a service provider for taxation for trust companies and manufacturing and shipping companies. He has gained a significant amount of commercial experience, which he brings to the provision of any advice provided.
Rachel V. Gow, PHD
Rachel is a guest researcher and Lead Associate Investigator of the Neuroimaging, Omega‐3 and Reward in Adults with ADHD (NORAA) trial at the National Institutes of Health (NIH) in Bethesda, Maryland, U.S. This study was the first randomized, double‐blind, placebo‐controlled, clinical trial to test the effects of omega‐3 fats in the brain activity of adults with ADHD. Prior to this role, Dr. Gow was awarded a Ph.D in Child Neuropsychology from the Institute of Psychiatry, King’s College London. During this Dr. Gow worked in the Department of Child and Adolescent Psychiatry and conducted clinical research in children/adolescents with and without ADHD investigating blood measures of omega-3 fatty acids and assessments of brain function using EEG and Event Related Potentials. Dr. Gow has a Master of Science in Psychological Research Methods (Distinction) from Birkbeck University of London. Dr. Gow’s under-graduate Psychology degree which was awarded First Class with Honors from the University of Kingston, London, accredited also by the British Psychological Society.
Russell is passionate about meaningful healthcare improvement and wellness, in the Isle of Man where he was born, and beyond. He has broad consulting and leadership experience with specialism in service design, facilitation, systems thinking and managing complexity. Currently working projects that move health services towards care that is integrated; making the most of digital technology. Russell’s primary interest is how people and systems really learn. In his career, he has looked at this problem through the lens of social history, in high risk environments as an outdoor instructor, as a management consultant and within the National Health Service. He is engaged in a research project with the International Bateson Institute to gain a deeper understanding of what learning means for avoidable ill health. Russell is an active member of the Society for Cybernetics in Organisations (SCiO), the Relating Systems and Design conference, and a fellow of the RSA.
Julie has over 30 years’ clinical and leadership experience holding executive positions in both national and multinational organisations in the UK and The Middle East. Highly analytical, Julie has a proven track record in successfully developing and leading innovative and effective improvement strategies in response to an increasingly complex and challenging health & social care environment. Julie has been personally appointed to develop a number of healthcare start-up companies adopting alternative business models and developing alternative strategies to build robust healthcare organisations that are built on humanitarian healthcare principles. These strategies have cemented strategic collaborations with the NHS, Clinical Commissioning Groups, Private Health Care Providers and International Partners.
Graham is a Psychotherapist, restorative counsellor and trainer holding an MA in Counselling as well as Post-Graduate qualifications in psychotherapy. He has a deep understanding and passion for working with the most isolated, vulnerable and hurt members of society. His fulfilment comes from restorative therapy. He has worked at the most challenging and extreme edges of therapy in a variety of settings. These include: therapeutic communities, social enterprises within the mental health field and criminal justice system, as well as homeless hostels and addiction centres. Graham’s passion for working with this often neglected part of society is simple: he has been there personally, previously, and now seeks to help others move through those experiences. His research interests include how people change; seeing criminality, mental health and addiction as a developmental problem rather than a moral or medical issue for society. His perspective is in looking at rehabilitation and recovery systems from a far more holistic view point. Graham is currently involved in a community driven project helping marginalised individuals re-integrate into society. He is also developing a wearable ‘experiential learning technology’ for restorative psychological wellness, initially targeting addicts and offenders.
Mark Whitney is Founder and Managing Director of Pillar Healthcare Ltd., a leading nutritional company specialising in endocrinological health. Having obtained his qualifications in business studies and nutritional science, Mark set out to change the way we looked at nutrition, its role in health and fighting disease and illness. Mark pioneered Europe’s first pilot study to assess the impact of a nutraceutical supplement on fertility parameters in both men and women. This study was initiated on the Isle of Man, British Isles. Following on from the pilot study’s success, Mark has developed this concept into a larger multi-country, multi-centered international clinical trial, due to start late 2017. Mark has also developed nutritional formulations for several well-known nutritional brands in Ireland and the UK and sits on many expert panels within this field. When Mark is not busy trying to convince the world there is a better way to treat patients through nutrition and supplementation, he is a keen humanitarian and has spent time in Vietnam helping to build social networks in vulnerable communities.